440 related articles for article (PubMed ID: 28701859)
1. Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin's lymphoma with an emphasis on targeted therapies and transplantation strategies.
Karantanos T; Politikos I; Boussiotis VA
Blood Lymphat Cancer; 2017; 7():37-52. PubMed ID: 28701859
[TBL] [Abstract][Full Text] [Related]
2. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
Moskowitz CH; Nademanee A; Masszi T; Agura E; Holowiecki J; Abidi MH; Chen AI; Stiff P; Gianni AM; Carella A; Osmanov D; Bachanova V; Sweetenham J; Sureda A; Huebner D; Sievers EL; Chi A; Larsen EK; Hunder NN; Walewski J;
Lancet; 2015 May; 385(9980):1853-62. PubMed ID: 25796459
[TBL] [Abstract][Full Text] [Related]
3. A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation.
Taçyıldız N; Tanyıldız HG; Ünal E; Dinçaslan H; Asarcıklı F; Aksoy BA; Vatansever G; Yavuz G
Turk J Pediatr; 2019; 61(5):671-676. PubMed ID: 32104998
[TBL] [Abstract][Full Text] [Related]
4. [Reaserch Advance on Treatment Strategies for Relapsed/Refractory Hodgkin's Lymphoma--Review].
Jin DC; Zhao L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Feb; 28(1):343-349. PubMed ID: 32027301
[TBL] [Abstract][Full Text] [Related]
5. Advances in CD30- and PD-1-targeted therapies for relapsed or refractory Hodgkin lymphoma.
Ma H; Li X; Lin M; Lv K; Zhang M; Wu X
Am J Transl Res; 2021; 13(11):12206-12216. PubMed ID: 34956447
[TBL] [Abstract][Full Text] [Related]
6. Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study.
Locatelli F; Mauz-Koerholz C; Neville K; Llort A; Beishuizen A; Daw S; Pillon M; Aladjidi N; Klingebiel T; Landman-Parker J; Medina-Sanson A; August K; Sachs J; Hoffman K; Kinley J; Song S; Song G; Zhang S; Suri A; Gore L
Lancet Haematol; 2018 Oct; 5(10):e450-e461. PubMed ID: 30290902
[TBL] [Abstract][Full Text] [Related]
7. Current and emerging treatment options for a patient with a second relapse of Hodgkin's lymphoma.
Kallam A; Armitage JO
Expert Rev Hematol; 2018 Apr; 11(4):293-300. PubMed ID: 29521140
[TBL] [Abstract][Full Text] [Related]
8. Reappraising the Role of Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed and Refractory Hodgkin's Lymphoma: Recent Advances and Outcomes.
Al-Juhaishi T; Borogovac A; Ibrahimi S; Wieduwilt M; Ahmed S
J Pers Med; 2022 Jan; 12(2):. PubMed ID: 35207613
[TBL] [Abstract][Full Text] [Related]
9. Novel Therapies and Approaches to Relapsed/Refractory HL Beyond Chemotherapy.
Mina AA; Vakkalagadda C; Pro B
Cancers (Basel); 2019 Mar; 11(3):. PubMed ID: 30934568
[TBL] [Abstract][Full Text] [Related]
10. Brentuximab vedotin for the treatment of Hodgkin's lymphoma.
Pham A; Chen R
Expert Rev Hematol; 2015 Aug; 8(4):403-12. PubMed ID: 25967932
[TBL] [Abstract][Full Text] [Related]
11. Novel Salvage Therapy Options for Initial Treatment of Relapsed/Refractory Classical Hodgkin's Lymphoma: So Many Options, How to Choose?
Takiar R; Karimi Y
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884585
[TBL] [Abstract][Full Text] [Related]
12. The role of hematopoietic stem cell transplantation in the treatment of relapsed/refractory Hodgkin's lymphoma.
Sureda A; Pereira MI; Dreger P;
Curr Opin Oncol; 2012 Nov; 24(6):727-32. PubMed ID: 23079783
[TBL] [Abstract][Full Text] [Related]
13. Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients.
Zinzani PL; Pellegrini C; Cantonetti M; Re A; Pinto A; Pavone V; Rigacci L; Celli M; Broccoli A; Argnani L; Pulsoni A
Oncologist; 2015 Dec; 20(12):1413-6. PubMed ID: 26500229
[TBL] [Abstract][Full Text] [Related]
14. Prolonged Remission by Pembrolizumab and Brentuximab-Vedotin Combination Therapy in Heavily-Pretreated Relapsed/Refractory Hodgkin's Lymphoma.
Yu TY; Dai MS
J Hematol; 2020 Apr; 9(1-2):30-32. PubMed ID: 32362983
[TBL] [Abstract][Full Text] [Related]
15. New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.
Merli M; Ferrario A; Maffioli M; Olivares C; Stasia A; Arcaini L; Passamonti F
Expert Rev Hematol; 2016 Aug; 9(8):767-80. PubMed ID: 27416486
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for the treatment of Hodgkin lymphoma.
Donato EM; Fernández-Zarzoso M; De La Rubia J
Expert Rev Hematol; 2017 May; 10(5):417-423. PubMed ID: 28359170
[TBL] [Abstract][Full Text] [Related]
17. Brentuximab vedotin for treating Hodgkin's lymphoma: an analysis of pharmacology and clinical efficacy.
Illés Á; Jóna Á; Miltényi Z
Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):451-9. PubMed ID: 25642958
[TBL] [Abstract][Full Text] [Related]
18. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data.
Bonthapally V; Wu E; Macalalad A; Yang H; Shonukan O; Liu Y; Chi A; Huebner D
Curr Med Res Opin; 2015 May; 31(5):993-1001. PubMed ID: 25772232
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma.
Voorhees TJ; Beaven AW
Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33050054
[TBL] [Abstract][Full Text] [Related]
20. Determining the sequence of novel therapies in the treatment of relapsed Hodgkin's lymphoma.
Narkhede M; Sarraf Yazdy M; Cheson B
Expert Rev Hematol; 2018 Oct; 11(10):773-780. PubMed ID: 30139285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]